Accumulating evidence suggests that WT1 is also expressed in many different classes of intracranial tumors, including gliomas (Izumoto et al., 2008), oligodendrogliomas (Rauscher et al., 2014), ependymomas (Yeung et al., 2013), and meningiomas (Iwami et al., 2013) and functions as an oncogene in these tumors. Here, WT1 is linked to central nervous system cancer.